7.2 Acquired Coagulation Factor Deficiencies, Circulating Inhibitors & DIC

Acquired Coagulation Factor Deficiencies, Circulating Inhibitors & DIC

Acquired bleeding disorders are far more common at the bench than the hereditary hemophilias, and the ASCP BOC lists acquired factor deficiencies, inhibitors, and disseminated intravascular coagulation as separate disease-state topics. The recurring examination task is to read a PT/APTT/platelet/fibrinogen/D-dimer panel and decide whether the patient has failed production, accelerated consumption, dilution, or a circulating antibody.

---

1. Deficiencies of Production and Clearance

Unlike inherited single-factor deficiencies, acquired coagulopathies typically involve multiple factor abnormalities occurring secondary to underlying systemic diseases.

                            [ ACQUIRED COAGULOPATHY DIFFERENTIAL ]

            CRITERIA                       VITAMIN K DEFICIENCY             SEVERE LIVER DISEASE
  ─────────────────────────────────────────────────────────────────────────────────────────────────
  Initial Prolonged Test           PT prolongs first (FVII short t1/2)  Both PT and aPTT prolonged
  Factor VIII Activity             STRICTLY NORMAL                      ELEVATED (Endothelial synthesis)
  von Willebrand Factor (vWF)      STRICTLY NORMAL                      ELEVATED (Endothelial synthesis)
  Fibrinogen Level                 NORMAL                               Decreased / Dysfibrinogenemic
  Platelet Count                   NORMAL                               Thrombocytopenia (Hypersplenism)
  Reversal / Correction            Parenteral Vitamin K1                4F-PCC / FFP / Liver transplant

1. Vitamin K Deficiency

• Biochemical Mechanism: Vitamin K is an essential fat-soluble cofactor required by hepatic microsomal $\gamma$-glutamyl carboxylase to convert specific glutamic acid (Glu) residues into $\gamma$-carboxyglutamic acid (Gla) on the amino-terminal domains of vitamin K-dependent procoagulant factors (Factors II, VII, IX, and X) and regulatory anticoagulant proteins (Protein C, Protein S, and Protein Z). Gla residues bind ionized calcium ($Ca^{2+}$), allowing these enzymes to anchor to negatively charged phosphatidylserine on activated platelets.
• Consequence of Deficiency: In the absence of vitamin K, the liver secretes uncarboxylated, functionally inert molecules known as PIVKAs (Proteins Induced by Vitamin K Absence/Antagonism), which cannot bind calcium or participate in clot assembly.
• Coagulation Profile Dynamics:
  • Factor VII has the shortest biological half-life of all coagulation factors (~4 to 6 hours).
  • Consequently, in developing vitamin K deficiency, the Prothrombin Time (PT / INR) prolongs FIRST, while the aPTT remains normal.
  • As the deficiency progresses, Factor IX ($t_{1/2} \approx 24\text{ hours}$), Factor X ($t_{1/2} \approx 36\text{ hours}$), and Prothrombin/FII ($t_{1/2} \approx 60\text{ hours}$) become depleted, causing subsequent prolongation of the aPTT.
  • Thrombin Time, Fibrinogen, Factor V, Factor VIII, and Platelet Count remain completely NORMAL.
• Common Clinical Etiologies:
  • Prolonged broad-spectrum antibiotic administration (sterilizes intestinal microflora producing vitamin $K_2$ / menaquinone).
  • Biliary tract obstruction, cholestatic jaundice, or fat malabsorption syndromes (celiac disease, Crohn's, cystic fibrosis).
  • Hemorrhagic Disease of the Newborn (Vitamin K Deficiency Bleeding / VKDB): Neonates possess low hepatic vitamin K stores, poor placental transfer, minimal vitamin K concentrations in human breast milk, and a sterile gut devoid of bacterial synthesis; routinely prevented by prophylactic intramuscular administration of Vitamin $K_1$ at birth.

2. Coagulopathy of Severe Liver Disease

• Pathophysiology: The liver parenchymal hepatocyte is the primary site of synthesis for nearly all procoagulant factors (Fibrinogen, Prothrombin, FV, FVII, FIX, FX, FXI, FXII, FXIII) and natural anticoagulants (Antithrombin, Protein C, Protein S).
• The Crucial Laboratory Diagnostic Dichotomy:
  • Factor VIII and vWF are NOT synthesized by hepatocytes. They are produced and secreted by vascular endothelial cells (and sinusoidal endothelial/Kupffer cells).
  • In acute and chronic liver failure, cirrhosis, and viral hepatitis, circulating Factor VIII and vWF levels are NORMAL or MARKEDLY ELEVATED (often $>200\text{--}400%$ of normal) as acute phase reactants and due to endothelial activation.
  • Distinguishing Liver Failure from Disseminated Intravascular Coagulation (DIC): Factor V and Factor VII are decreased in both conditions; however, Factor VIII is markedly elevated in uncomplicated liver disease, whereas Factor VIII is severely consumed and decreased in acute decompensated DIC.
• Additional Laboratory Manifestations of Liver Disease:
  • Dysfibrinogenemia: Hepatocytes produce abnormal fibrinogen molecules with increased sialic acid content, impairing fibrin monomer polymerization (prolonged TT and Reptilase time).
  • Thrombocytopenia: Caused by splenic pooling/sequestration secondary to portal hypertension, coupled with reduced hepatic synthesis of thrombopoietin (TPO).

---

2. Dilutional and Consumptive Acquired Deficiencies

Disseminated Intravascular Coagulation (DIC): The Coagulation Profile

DIC is systemic, uncontrolled activation of coagulation triggered by tissue factor entering the circulation (sepsis, obstetric catastrophe, trauma, crush injury, burns, acute promyelocytic leukemia, snake envenomation, malignancy). Thrombin is generated faster than the natural anticoagulants can quench it, microthrombi consume platelets and factors, and secondary fibrinolysis then dissolves fibrin and releases fibrin degradation products. The result is simultaneous thrombosis and bleeding.

Examination discriminators. D-dimer detects only cross-linked fibrin, so it is raised in DIC but NOT in primary fibrinolysis or in pure hypofibrinogenemia; the FDP assay cannot make that distinction because it also detects fibrinogenolysis products. In thrombotic thrombocytopenic purpura the platelet count is low and schistocytes are prominent, but PT, APTT, fibrinogen, and D-dimer are essentially NORMAL, because TTP is a platelet-VWF disease rather than a coagulation-factor disease. Chronic (compensated) DIC, typical of adenocarcinoma, may show a normal platelet count and normal screening times with an isolated raised D-dimer.

Liver Disease versus Vitamin K Deficiency: The Factor V Rule

Both prolong the PT first. Only the liver synthesizes factor V, and factor V is NOT vitamin K dependent.

• Vitamin K deficiency or warfarin effect: factor VII decreased, factor V NORMAL, corrected by parenteral vitamin K.
• Hepatocellular failure: factor VII decreased AND factor V DECREASED, not corrected by vitamin K. Factor VIII is normal or elevated in liver disease because it is made by endothelium, which further separates it from DIC, where factor VIII falls.

Dilutional Coagulopathy of Massive Transfusion

Replacement of more than one blood volume with crystalloid and stored red cells dilutes platelets and labile factors V and VIII. Hypothermia and acidosis independently impair enzyme kinetics and platelet function, and citrate load chelates ionized calcium. The laboratory picture is a prolonged PT and APTT with thrombocytopenia and hypofibrinogenemia but a normal or only mildly raised D-dimer, which separates it from consumptive DIC.

---

3. Circulating Inhibitors

An inhibitor is an immunoglobulin that neutralizes a coagulation factor or interferes with phospholipid-dependent assembly. The mixing study is the screening tool: an inhibitor fails to correct on a 1:1 mix with normal pooled plasma, whereas a factor deficiency corrects.

Time and temperature dependence is the classic examination cue. A factor VIII inhibitor is progressive: the immediate 1:1 mix may look nearly corrected, and only after 1 to 2 hours of incubation at 37 C does the APTT become clearly prolonged. A lupus anticoagulant inhibits immediately and shows no incubation effect. A Bethesda unit is defined as the amount of inhibitor that neutralizes 50% of factor VIII activity in normal plasma after 2 hours of incubation at 37 C; the Nijmegen modification buffers the normal pooled plasma with imidazole and uses factor VIII-deficient plasma as the diluent to improve specificity at low titers.